Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
NCT02972320
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG:
temozolomide
Sponsor
Yunpeng Liu